데스플루란 시장 : 세계 예측(2026-2032년)

The Desflurane Market is projected to grow by USD 916.19 million at a CAGR of 8.47% by 2032.

Desflurane is a volatile inhaled anesthetic used to maintain general anesthesia, particularly when rapid emergence and controllable anesthetic depth are clinically valuable. Its role is being reassessed because of environmental impact, operating-room emissions controls, procurement priorities, and the availability of alternative anesthetic approaches. Decision-making increasingly requires balancing clinical workflow, patient suitability, regulatory expectations, and sustainability objectives rather than evaluating the agent on pharmacologic performance alone.

Environmental Policy Is Reshaping Desflurane Use

The most consequential shift is the growing recognition that desflurane has a high global-warming potential relative to several alternative anesthetic gases. Hospitals and health systems are responding through lower-emission formularies, substitution protocols, waste-reduction practices, and measurement of operating-room greenhouse-gas emissions. Regulatory restrictions and institutional climate commitments are reinforcing this transition, while clinical exceptions remain relevant where anesthesiologists determine that desflurane offers workflow or patient-management advantages.

Artificial Intelligence Improves Stewardship and Clinical Decision Support

Artificial intelligence can strengthen desflurane stewardship by combining anesthesia records, ventilation data, procedure characteristics, recovery times, and emissions factors to identify avoidable use and support clinician review. Predictive tools may help anticipate emergence requirements, optimize fresh-gas flows, detect unusual consumption, and compare practice patterns across operating rooms. These applications require validated models, transparent recommendations, privacy safeguards, and clinician oversight; AI should support-not replace-individualized anesthetic judgment or institutional governance.

Regional Insights: Uneven Adoption Reflects Policy and Infrastructure

North America is emphasizing environmental procurement, hospital sustainability programs, and protocol-based substitution, although practice varies by institution and clinical context. Europe has generally shown stronger policy momentum toward reducing high-impact anesthetic gases, supported by national and health-system decarbonization initiatives. Asia-Pacific combines advanced hospital systems with rapidly expanding surgical capacity, creating varied adoption patterns across countries. Latin America, the Middle East, and Africa face differing levels of access, infrastructure, training capacity, and regulatory coordination; implementation is therefore likely to depend on local supply conditions and practical operating-room resources.

Group Insights: Regional Alliances Influence Standards and Procurement

Within ASEAN, differences in health-system maturity and procurement capacity can produce varied approaches to desflurane stewardship. BRICS members span major pharmaceutical and healthcare systems with distinct regulatory priorities, making coordinated policy difficult but potentially influential. The European Union provides a comparatively integrated setting for environmental and healthcare policy development. G7 members are positioned to influence sustainable anesthesia practice through clinical guidance, public procurement, and emissions reporting. GCC countries may advance adoption through centralized or coordinated hospital systems, while NATO members reflect a broad range of health infrastructures and regulatory environments rather than a single purchasing model.

Country Insights: National Context Determines Clinical and Environmental Priorities

Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States are evaluating desflurane through the combined lenses of perioperative quality, emissions reduction, and institutional procurement. Brazil, Mexico, India, China, Russia, Japan, and South Korea present diverse combinations of surgical demand, domestic manufacturing, regulatory practice, and hospital capability. Country-level decisions should account for clinical indications, supply continuity, local environmental policy, anesthesiology guidance, and the feasibility of alternatives rather than relying on a uniform global policy.

Actions for Leaders: Link Clinical Governance With Emissions Reduction

Industry leaders should establish a multidisciplinary anesthetic-gas policy involving anesthesiology, pharmacy, procurement, facilities, sustainability, and finance teams. They should measure desflurane consumption and associated emissions, define evidence-based exceptions, promote low-flow techniques where clinically appropriate, and provide practical training on alternatives and vaporizer management. Procurement teams should assess lifecycle impact and supply resilience, while executives should monitor recovery outcomes, operating-room efficiency, clinician acceptance, and unintended effects of substitution. Transparent reporting and periodic protocol review can align environmental goals with patient safety.

Methodology: Evidence-Based Interpretation of Clinical and Policy Signals

This executive summary uses the supplied market subject-desflurane-and synthesizes established clinical, environmental, regulatory, and health-system considerations without presenting market estimates, shares, forecasts, or company-specific claims. The analysis treats the required regions, country groupings, and countries as contextual lenses for comparing policy environments, infrastructure, procurement practices, and implementation readiness. Conclusions should be validated against current national guidance, institutional utilization data, peer-reviewed clinical evidence, and verified emissions methodologies before operational decisions are made.

Conclusion: Desflurane Decisions Require Balanced, Locally Validated Governance

Desflurane remains a clinically relevant anesthetic, but its environmental profile is changing how hospitals assess its place in practice. The strongest response is neither indiscriminate continuation nor blanket substitution; it is disciplined governance that identifies appropriate use, reduces avoidable emissions, supports clinicians with reliable alternatives, and preserves patient-centered care. Regional and national differences make local evidence, transparent measurement, and continuous review essential to responsible decision-making.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Desflurane Market, by Packaging Type

• 7.1. Introduction
• 7.2. Multi Dose Vials
• 7.3. Single Dose Vials

8. Desflurane Market, by Application

• 8.1. Introduction
• 8.2. Cardiology
  • 8.2.1. Bypass Surgery
  • 8.2.2. Valve Replacement
• 8.3. General Surgery
  • 8.3.1. Laparoscopic Surgery
  • 8.3.2. Open Surgery
• 8.4. Obstetrics & Gynecology
  • 8.4.1. Cesarean Section
  • 8.4.2. Natural Birth
• 8.5. Orthopedics
  • 8.5.1. Joint Replacement
  • 8.5.2. Spinal Surgery

9. Desflurane Market, by End User

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
  • 9.2.1. Freestanding
  • 9.2.2. Hospital Affiliated
• 9.3. Clinics
  • 9.3.1. Outpatient Clinics
  • 9.3.2. Specialty Clinics
• 9.4. Hospitals
  • 9.4.1. Private
  • 9.4.2. Public

10. Desflurane Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Desflurane Market, by Region

• 11.1. Introduction
• 11.2. Asia-Pacific
• 11.3. North America
• 11.4. Latin America
• 11.5. Europe
• 11.6. Middle East
• 11.7. Africa

12. Desflurane Market, by Group

• 12.1. Introduction
• 12.2. ASEAN
• 12.3. GCC
• 12.4. European Union
• 12.5. BRICS
• 12.6. G7
• 12.7. NATO

13. Desflurane Market, by Country

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. United Kingdom
• 13.7. Germany
• 13.8. France
• 13.9. Russia
• 13.10. Italy
• 13.11. Spain
• 13.12. China
• 13.13. India
• 13.14. Japan
• 13.15. Australia
• 13.16. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. Market Concentration Analysis, 2025
  • 14.2.1. Concentration Ratio (CR)
  • 14.2.2. Herfindahl Hirschman Index (HHI)
• 14.3. Recent Developments & Impact Analysis, 2025
• 14.4. Product Portfolio Analysis, 2025
• 14.5. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. AbbVie Inc.
• 15.3. Alcon Inc.
• 15.4. Alembic Pharmaceuticals Ltd.
• 15.5. AstraZeneca PLC
• 15.6. B. Braun Melsungen AG
• 15.7. Baxter International Inc.
• 15.8. Boehringer Ingelheim International GmbH
• 15.9. Cipla Ltd.
• 15.10. Dr. Reddy's Laboratories Ltd.
• 15.11. Emcure Pharmaceuticals Ltd.
• 15.12. Fresenius Kabi AG
• 15.13. GlaxoSmithKline plc
• 15.14. Hikma Pharmaceuticals plc
• 15.15. Intas Pharmaceuticals Ltd.
• 15.16. Johnson & Johnson Services, Inc.
• 15.17. Lupin Limited
• 15.18. Macleods Pharma Ltd.
• 15.19. Merck & Co., Inc.
• 15.20. Mylan N.V.
• 15.21. Novartis AG
• 15.22. Orion Corporation
• 15.23. Pfizer Inc.
• 15.24. Sandoz International GmbH
• 15.25. Sanofi S.A.
• 15.26. Sun Pharmaceutical Industries Ltd.
• 15.27. Teva Pharmaceutical Industries Ltd.
• 15.28. Torrent Pharmaceuticals Ltd.
• 15.29. Viatris Inc.
• 15.30. Zydus Lifesciences Ltd.

16. Key Experts